RGS4 exerts inhibitory activities on the signaling of dopamine D2 receptor and D3 receptor through the N-terminal region.

[1]  K. Kwon,et al.  Novel Regulatory Mechanism of Canonical Wnt Signaling by Dopamine D2 Receptor through Direct Interaction with β-Catenin , 2011, Molecular Pharmacology.

[2]  Kyeong-Man Kim,et al.  Current perspectives on the selective regulation of dopamine D2 and D3 receptors , 2010, Archives of pharmacal research.

[3]  R. Gur,et al.  RGS4 polymorphisms associated with variability of cognitive performance in a family-based schizophrenia sample. , 2010, Schizophrenia bulletin.

[4]  Meenakshi Sharma,et al.  RGS9‐2 mediates specific inhibition of agonist‐induced internalization of D2‐dopamine receptors , 2010, Journal of neurochemistry.

[5]  Kyeong-Man Kim,et al.  Agonist-induced endocytosis and receptor phosphorylation mediate resensitization of dopamine D(2) receptors. , 2010, Molecular endocrinology.

[6]  T. K. Harden,et al.  Crystal structure of the multifunctional Gβ5–RGS9 complex , 2008, Nature Structural &Molecular Biology.

[7]  E. Kuzhikandathil,et al.  The tolerance property of human D3 dopamine receptor is determined by specific amino acid residues in the second cytoplasmic loop. , 2007, Biochimica et biophysica acta.

[8]  M. Caron,et al.  Roles of protein kinase C and actin-binding protein 280 in the regulation of intracellular trafficking of dopamine D3 receptor. , 2007, Molecular endocrinology.

[9]  B. O'dowd,et al.  D1–D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum , 2007, Proceedings of the National Academy of Sciences.

[10]  D. Collier,et al.  Evaluation of a Susceptibility Gene for Schizophrenia: Genotype Based Meta-Analysis of RGS4 Polymorphisms from Thirteen Independent Samples , 2006, Biological Psychiatry.

[11]  R. Gainetdinov,et al.  G Protein-coupled Receptor Kinase Regulates Dopamine D3 Receptor Signaling by Modulating the Stability of a Receptor-Filamin-β-Arrestin Complex , 2005, Journal of Biological Chemistry.

[12]  Johannes Schwarz,et al.  D2 Dopamine Receptors Colocalize Regulator of G-Protein Signaling 9-2 (RGS9-2) via the RGS9 DEP Domain, and RGS9 Knock-Out Mice Develop Dyskinesias Associated with Dopamine Pathways , 2005, The Journal of Neuroscience.

[13]  H. Lester,et al.  Neurobiology of Disease D 2 Dopamine Receptors Colocalize Regulator of G-Protein Signaling 9-2 ( RGS 9-2 ) via the RGS 9 DEP Domain , and RGS 9 Knock-Out Mice Develop Dyskinesias Associated with Dopamine Pathways , 2005 .

[14]  D. Surmeier,et al.  RGS9-2 modulates D2 dopamine receptor-mediated Ca2+ channel inhibition in rat striatal cholinergic interneurons. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  C. Tamminga,et al.  Regional expression of RGS4 mRNA in human brain † , 2004, The European journal of neuroscience.

[16]  J. Leysen,et al.  Dopamine receptor‐mediated regulation of RGS2 and RGS4 mRNA differentially depends on ascending dopamine projections and time , 2004, The European journal of neuroscience.

[17]  Erik Schiørring,et al.  An open field study of stereotyped locomotor activity in amphetamine-treated rats , 2004, Psychopharmacology.

[18]  Hoo-Kyun Choi,et al.  Direct and biochemical interaction between dopamine D3 receptor and elongation factor-1Bbetagamma. , 2003, Life sciences.

[19]  Johannes Schwarz,et al.  RGS9 Modulates Dopamine Signaling in the Basal Ganglia , 2003, Neuron.

[20]  J. Leysen,et al.  Striatal gene expression of RGS2 and RGS4 is specifically mediated by dopamine D1 and D2 receptors: clues for RGS2 and RGS4 functions , 2003, Journal of neurochemistry.

[21]  A. Kopin,et al.  A Drosophila dopamine 2-like receptor: Molecular characterization and identification of multiple alternatively spliced variants , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Caron,et al.  Differential Regulation of the Dopamine D2and D3 Receptors by G Protein-coupled Receptor Kinases and β-Arrestins* , 2001, The Journal of Biological Chemistry.

[23]  D. Lewis,et al.  Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia , 2001, Molecular Psychiatry.

[24]  S. Heximer,et al.  G Protein Selectivity Is a Determinant of RGS2 Function* , 1999, The Journal of Biological Chemistry.

[25]  S. Muallem,et al.  RGS Proteins Determine Signaling Specificity of Gq-coupled Receptors* , 1999, The Journal of Biological Chemistry.

[26]  S. Muallem,et al.  The N-terminal Domain of RGS4 Confers Receptor-selective Inhibition of G Protein Signaling* , 1998, The Journal of Biological Chemistry.

[27]  S. Muallem,et al.  The N-terminal Domain of RGS 4 Confers Receptor-selective Inhibition of G Protein Signaling , 1998 .

[28]  C. Stratowa,et al.  Functional testing of human dopamine D1 and D5 receptors expressed in stable cAMP-responsive luciferase reporter cell lines. , 1993, Journal of receptor research.

[29]  M. Besser,et al.  Management of prolactinomas , 1991, Clinical endocrinology.

[30]  P. Seeman,et al.  Dopamine receptors and transporters in Parkinson's disease and schizophrenia , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  P. Seeman,et al.  Dopamine receptors and the dopamine hypothesis of schizophrenia , 1987, Synapse.

[32]  R. Wise,et al.  The role of reward pathways in the development of drug dependence. , 1987, Pharmacology & therapeutics.

[33]  P. L. Carlton,et al.  Dopamine and schizophrenia: An analysis of the theory , 1984, Neuroscience & Biobehavioral Reviews.

[34]  Y. Nomura,et al.  High potassium-induced, calcium-dependent monoamine release from brain slices of the newborn rat. , 1979, Japanese journal of pharmacology.

[35]  P. Leigh,et al.  Treatment of parkinsonism with bromocriptine. , 1974, Lancet.

[36]  S. Matthysse.  Antipsychotic drug actions: a clue to the neuropathology of schizophrenia? , 1973, Federation proceedings.

[37]  O. Hornykiewicz.  Dopamin (3-Hydroxytyramin) im Zentralnervensystem und seine Beziehung zum Parkinson-Syndrom des Menschen , 1962 .

[38]  O. Hornykiewicz.  [Dopamine (3-hydroxytyramine) in the central nervous system and its relation to the Parkinson syndrome in man]. , 1962, Deutsche medizinische Wochenschrift.